Calcium-sensitive switch boosts the efficacy of cancer drugs

The calcium-regulated protein drug (green) and tumor cell receptors (red) have bonded and internalization is underway, 40 seconds after administration.

ImageKTH

The calcium switch is built into the drug design

A research team from KTH, Stanford University and Umeå University has developed a calcium activated delivery system that could enable more precise treatment, with lower doses and less collateral damage to healthy tissue. The results have been published inin PNAS, the journal of the National Academy of Sciences.

The concept takes aim at a common challenge with targeted drugs, which tend to cling too tightly to receptors expressed by tumors. On the positive side, that strong bond blocks receptors’ tumor growth signals. But ADCs (Antibody–Drug Conjugates) are also meant to attack and kill, and too often the protein can become stuck without ever penetrating deeper into the cell’s real intended goal: an acidic compartment called the lysosome. There, in the kill zone, the targeting protein can be broken down, thus unleashing toxin that causes cell death. 

Calcium dependent bond

To avoid that problem, the researchers developed a calcium-sensitive switch that binds strongly to the cancer cell receptor on the outside of the cell where relatively high calcium concentrations are found, in the blood and the extracellular fluid.

Once bound together, the drug-loaded protein (or calcium-regulated affinity, CaRA) and epidermal growth factor receptor (EGFR) are pulled inside the cell, into compartments with gradually lower levels of calcium. And because their bond is calcium dependent, the receptor and CaRA eventually go their separate ways: the receptor can recycle back to the membrane, while CaRA continues carrying its payload toward the lysosome.

“The calcium switch is built into the drug design. It senses calcium levels and changes its grip automatically,” says Sophia Hober, professor at KTH Royal Institute of Technology who led the study.

From Umeå University, Professor Magnus Wolf-Watz's group participated in the study published in PNAS.

ImageMattias Pettersson

Very selective molecule

The study was performed on living human cancer cell lines, using a payload of the cytotoxin, mertansine DM1. The drug conjugate showed a very high potency and it is highly selective—it only killed cells that overexpress EGFR, leaving healthy or low-EGFR cells unharmed. The researchers emphasize that this shows specific targeting and a strong therapeutic window, which is critical for reducing side effects.

Leon Schierholz, a doctoral student in Magnus Wolf-Watz's research group at Umeå University, has determined a low-resolution structure of the complex between CaRA; and the extracellular domain of the EGFR receptor. The structure has been determined to a resolution of approximately 6 Å using the single particle cryoEM technique on data collected at the Umeå Centre for Electron Microscopy, UCEM, at Umeå University.

The structure provides a fundamental molecular understanding of the high affinity of the complex.

PDoctoral student Léon Schierholz has spent many hours at the large microscope at the UCEM technology platform at Umeå University.

ImageHans Karlsson

Next step an atomic model

“We are now moving forward and aiming to come up with a high-resolution structure with a resolution below 3.5 Å that can allow us to make an atomic model that can be used to further improve the properties of CaRA. The data is of very good quality for this relatively small complex,” says Leon Schierholz, who in this context wants to put the spotlight on his colleague Max Renner, who is highly involved in completing the atomic model.